ArticleFrontiers in immunology2025
TBA-MLR score: a metabolic-immune prognostic biomarker for postoperative hepatocellular carcinoma.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development and Validation of a LASSO-RF-Cox-Derived Nomogram Incorporating Inflammatory Markers to Predict Long-Term Survival in Early-Stage Hepatocellular Carcinoma After Microwave Ablation.Journal of hepatocellular carcinoma · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To develop and validate a novel prognostic score combining serum total bile acid (TBA) and monocyte-to-lymphocyte ratio (MLR) for improved risk stratification in hepatocellular carcinoma (HCC) patients after radical hepatectomy. Methods: In 508 HCC patients undergoing radical hepatectomy, we determined optimal TBA and MLR cutoffs for RFS and OS using maximally selected rank statistics. Multivariable Cox regression identified independent predictors, enabling development of a three-tiered TBA-MLR risk score (low/intermediate/high). We internally validated performance via bootstrapping (1000 iterations) and compared it against conventional biomarkers (AFP, BCLC, Child-Pugh) and inflammatory indices (SII, SIRI, NLR, PLR). Subgroup analyses assessed its ability to refine prognosis within BCLC stages and AFP categories. Concordance and overlap were assessed via Venn diagrams and Cohen's kappa coefficient. Subgroup analyses assessed the robustness of the TBA-MLR score. Results: Elevated TBA (>11.7 μmol/L; HR=2.96, p<0.001) and MLR (>0.26; HR=1.64, p=0.001) independently predicted poorer RFS, while TBA (>14 μmol/L; HR=3.87, p<0.001) and MLR (>0.32; HR=1.54, p=0.036) were associated with worse OS. The TBA-MLR score stratified patients into distinct risk groups: high-risk patients had significantly lower 1/3/5-year RFS (66.9%/41.4%/19.1%) and OS (79.5%/51.1%/19.1%) versus low-risk patients (RFS:94.3%/80.8%/73.8%; OS:97.9%/90.8%/85.3%; HR=5.69 and 4.07, both p<0.001). Notably, it identified high-risk subsets within traditional low-risk categories: 22.7% of BCLC0-A patients were high-risk by TBA-MLR and had a 5-year OS of only 22.6% (vs. 86.2% in low-risk BCLC0-A patients, p<0.0001). Similarly, among patients with AFP <400 ng/mL, the high-risk group (21.9%) had a 5-year OS of 31.9% (vs. 82.7% in low-risk patients, p<0.0001). Internal validation confirmed strong predictive accuracy (C-indices: RFS 0.639, OS 0.683), with 1/3/5-year AUCs (RFS:0.657/0.660/0.771; OS:0.713/0.720/0.779) outperforming conventional biomarkers (all p<0.05). The score demonstrated minimal concordance with conventional systems (|κ|<0.06), with 16-25% of high-risk patients missed by BCLC/AFP criteria. Subgroup analyses showed consistent performance across tumor characteristics and treatments. Conclusion: The TBA-MLR score is a robust metabolic-immune prognostic biomarker that effectively uncovers occult high-risk biology within conventional staging systems, enabling precise postoperative risk stratification for individualized management, particularly for patients traditionally classified as low-risk (e.g., BCLC 0-A) or with non-elevated AFP.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.